Literature DB >> 19522464

Structural assessment and biological evaluation of two N3S bombesin derivatives.

Eleni Gourni1, Penelope Bouziotis, Dimitra Benaki, George Loudos, Stavros Xanthopoulos, Maria Paravatou-Petsotas, Maria Mavri-Vavagianni, Maria Pelecanou, Spyros C Archimandritis, Alexandra D Varvarigou.   

Abstract

The aim of the present study is the evaluation of the (99m)Tc complexes of two bombesin-like peptides: Gly1'-Gly2'-Cys3'-Aca-BN[2-14] (BN-1.1) and Gly1'-Gly2'-Cys3'-Aca-BN[7-14] (BN-1.1p). The BN derivatives were synthesized according to the solid phase peptide synthesis method, and characterized by ESI-MS and NMR. (185/187)Re-BN-1.1 and (185/187)Re-BN-1.1p were also identified by ESI-MS and NMR. The (99m)Tc complexes were stable over time in human plasma, while they degraded rapidly in kidney-liver homogenates. The peptides and their (99m)Tc complexes showed high affinity for the human GRP receptors expressed in PC-3 cells. The rate of internalization of these radiolabeled biomolecules was found to be time-dependent. Also, it was found that there was no long-term retention of the radioactive metabolites into the cells. Tissue distribution of the radiopeptides was evaluated in normal mice and in prostate cancer experimental models. Significant uptake of radioactivity was observed in the pancreas of PC-3 tumor-bearing SCID mice. Dynamic studies of both radiopeptides showed satisfactory tumor images.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19522464     DOI: 10.1021/jm900360d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo.

Authors:  Irene Tsiapa; George Loudos; Eirini A Fragogeorgi; Penelope Bouziotis; Dimitrios Psimadas; Stavros Xanthopoulos; Maria Paravatou-Petsotas; Lazaros Palamaris; Alexandra D Varvarigou; Dimitris Karnabatidis; George C Kagadis
Journal:  Cancer Biother Radiopharm       Date:  2014-12       Impact factor: 3.099

3.  A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Authors:  Kubra Durkan; Zongrun Jiang; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Rajendra Prasad Bandari; Ashley F Szczodroski; Liqin Liu; Yubin Miao; Tamila Stott Reynolds; Charles J Smith
Journal:  Nucl Med Biol       Date:  2013-11-28       Impact factor: 2.408

4.  3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2012-12-03       Impact factor: 5.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.